Elevai Labs Inc. Announces Positive Data Results
Elevai Labs, Inc. (NASDAQ: ELAB), a pioneering force in medical aesthetics, has announced the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data from the clinical study was internally reviewed by the Company, and the results indicate that Elevai enfinity™ is safe and well-tolerated, showing significant improvements across many aspects of skin appearance. Elevai seeks to publish the full study results in the near future.
Study Overview and Participants
The study assessed the use of twice-daily Elevai enfinity™, a topical exosome product, on 29 study participants over a 12-week period. The goal was to determine the efficacy of the product on facial appearance, including measurements like facial firmness, skin tone, wrinkles, and smoothness. The subjects included healthy individuals aged 40 to 70 years, presenting mild to moderate facial photoaging and sensitive skin.
Collaboration with Dr. Zoe Draelos
Elevai collaborated with Dr. Zoe Draelos, a board-certified dermatologist serving as the Principal Investigator. Dr. Draelos is renowned for her extensive experience in aesthetics and cosmetics, having led over 800 clinical studies over her 35-year career in dermatology.
Significance of the Study
“We were fortunate to collaborate with Dr. Draelos in conducting this pivotal clinical study on behalf of Elevai,” remarked Dr. Jordan R. Plews, PhD, Chief Executive Officer of Elevai Skincare Inc. “As a company that places science at the forefront of our mission, we recognize the significance of rigorously designing a study to validate the safety, effectiveness, and tolerability of our daily topical exosome serum, Elevai enfinity™.”
Innovative Formulation of Elevai Enfinity™
Elevai enfinity™ harnesses the power of potent next-generation stem cell technology combined with scientifically proven ingredients to create an advanced 8-in-1 serum. This innovative formulation leverages exosomes that work at a cellular level to support the skin’s natural repair mechanisms, contributing to a radiant and more youthful complexion.
The Growing Demand for Clinical Research
With the recent emergence and growth of topical exosomes within the aesthetic skincare market, there has been a pressing need for scientific research verifying the safety and tolerability of exosomes, in addition to their effectiveness for improving common signs of skin aging. Elevai is well-positioned to prioritize science and data as part of its commercial strategy as it moves into 2024 and beyond, utilizing clinical findings as a key differentiation point against competing exosome products. The Draelos clinical study marks the first Elevai Skincare study slated for publication, with additional research underway to further validate Elevai’s proprietary exosomes.
Insights from Leading Experts
M. Bradley Calobrace, MD, FACS, a leading rejuvenation expert and prominent customer of Elevai enfinity™, stated, “As a plastic surgeon, I believe it is imperative to see clinical evidence and data to fully understand the potential of topical exosome technology and how we can best utilize it for our patients. We eagerly anticipate further clinical validation studies from Elevai, as the category of regenerative aesthetics expands and patient demand increases for this innovative approach to skincare.”
About Elevai Labs Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics as well as treatments related to obesity and metabolic health. The Company operates a diverse portfolio, including three wholly owned subsidiaries: Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc.
About Elevai Skincare Inc.
Elevai Skincare Inc., a subsidiary of Elevai Labs Inc., is dedicated to developing and commercializing cutting-edge physician-dispensed skin and hair care applications. The company emphasizes leveraging novel proprietary technologies, particularly its proprietary stem cell exosome technology, to create advanced cosmetic products for the physician-dispensed market.
Contact Information
Investor Relations Contact:
Makenzie Mann
contact@elevailabs.com
Frequently Asked Questions
What are the key findings from Elevai's clinical study?
The study indicated that Elevai enfinity™ is safe and well-tolerated, with notable improvements in facial firmness, skin tone, and overall skin appearance.
Who was involved in conducting the study?
The study was led by Dr. Zoe Draelos, a highly respected dermatologist with extensive experience in aesthetics.
What is Elevai enfinity™?
Elevai enfinity™ is a topical exosome product that utilizes advanced stem cell technology to improve the skin's natural repair mechanisms.
What is Elevai Labs' strategy for 2024?
Elevai aims to focus on scientific research and data to differentiate its products in the commercial market, with several studies planned for publication.
How can I contact Elevai Labs for more information?
For inquiries, you can contact Elevai Labs via email at contact@elevailabs.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lassila & Tikanoja Reports Increase in Shareholding
- North Bay Resources Reports High-Grade Gold Assays
- Urbo Bankas Reports Strong Growth in 2024 Financial Results
- Kauno energija AB Reports Strong Financial Growth for 2024
- AITX's RAD Achieves Positive Cash Flow Milestone
- LIXTE Begins Clinical Trial for Colorectal Cancer Treatment
- Asia Pacific Wire & Cable Corporation Limited Q2 2024 Results
- G2 Goldfields Showcases Strong Year-End Financial Results
- Golconda Gold Ltd. Financial Results for Q2 2024
- Alarum Technologies Reports Record Second Quarter 2024 Results